
|Videos|June 6, 2021
Investigative Treatment for Advanced Prostate Cancer Uses Targeted Approach
The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.
Advertisement
New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Researcher Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, said any kind of cancer therapy should be as targeted as possible in order to attack cancer cells while avoiding healthy cells. Therapy with 177Lu-PSMA-617 is very precise, Morris said, because it targets a specific molecule that is generally only expressed on the prostate cancer cell.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Executive Order Recommends Separating MMR Into 3 Shots
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
5




































































































